Literature DB >> 10477630

IgG and complement-mediated tissue damage in the absence of C2: evidence of a functionally active C2-bypass pathway in a guinea pig model.

E Wagner1, J L Platt, D N Howell, H C Marsh, M M Frank.   

Abstract

In vitro complement-mediated lysis of heavily sensitized sheep erythrocytes by C4-deficient (C4D) guinea pig and C2-deficient (C2D) human sera was demonstrated some years ago. It was postulated that these "complement-bypass" pathways resulted from activation of C1 and components of the alternative pathway. We used normal, C2D, and C4D guinea pigs in a Forssman shock model to test the in vivo relevance of the C2- and C4-bypass pathways of complement activation. High concentrations of both anti-Forssman Ab and C2D or C4D guinea pig serum induced efficient lysis of sheep erythrocytes in vitro. The most efficient lysis was observed when IgG Ab and C2D guinea pig serum were used. Blocking either the classical pathway (treatments with EGTA-Mg2+ or soluble recombinant complement receptor type 1 (sCR1)) or the alternative pathway (treatment with heating at 50 degrees C, sCR1, or soluble recombinant CR1 lacking the first of the four long homologous repeat sequences (sCR1[desLHR-A])) inhibited lysis; both pathways were required for lysis of sheep erythrocytes by C2D and C4D guinea pig sera. i.v. injection of anti-Forssman Ab in normal guinea pigs resulted in rapid death from pulmonary shock, whereas C4D guinea pigs had no adverse effect. Surprisingly, C2D guinea pigs either died in a delayed fashion or had a sublethal reaction. sCR1 treatment prevented Forssman shock in both normal and C2D guinea pigs, whereas sCR1[desLHR-A] prevented Forssman shock only in C2D animals. Our results suggest that the C2-bypass pathway occurs in vivo to produce tissue damage. Activation of complement in the absence of C2 appears to be far more efficient than in the absence of C4.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10477630

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Bypassing complement: evolutionary lessons and future implications.

Authors:  John P Atkinson; Michael M Frank
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

2.  Design of a complement mannose-binding lectin pathway-specific activation system applicable at low serum dilutions.

Authors:  M Harboe; P Garred; M S Borgen; G L Stahl; A Roos; T E Mollnes
Journal:  Clin Exp Immunol       Date:  2006-06       Impact factor: 4.330

Review 3.  Animal models of inherited complement deficiency.

Authors:  S Linton
Journal:  Mol Biotechnol       Date:  2001-06       Impact factor: 2.695

4.  Role of the classical pathway of complement activation in experimentally induced polymicrobial peritonitis.

Authors:  I Celik; C Stover; M Botto; S Thiel; S Tzima; D Künkel; M Walport; W Lorenz; W Schwaeble
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

5.  Deconstructing the Lectin Pathway in the Pathogenesis of Experimental Inflammatory Arthritis: Essential Role of the Lectin Ficolin B and Mannose-Binding Protein-Associated Serine Protease 2.

Authors:  Nirmal K Banda; Sumitra Acharya; Robert I Scheinman; Gaurav Mehta; Minoru Takahashi; Yuichi Endo; Wuding Zhou; Conrad A Farrar; Steven H Sacks; Teizo Fujita; Hideharu Sekine; V Michael Holers
Journal:  J Immunol       Date:  2017-07-24       Impact factor: 5.422

Review 6.  Recent developments in low molecular weight complement inhibitors.

Authors:  Hongchang Qu; Daniel Ricklin; John D Lambris
Journal:  Mol Immunol       Date:  2009-10-02       Impact factor: 4.407

7.  Recombinant human complement component C2 produced in a human cell line restores the classical complement pathway activity in-vitro: an alternative treatment for C2 deficiency diseases.

Authors:  Paolo G V Martini; Lynette C Cook; Scott Alderucci; Angela W Norton; Dianna M Lundberg; Susan M Fish; Knut Langsetmo; Göran Jönsson; Christian Lood; Birgitta Gullstrand; Kate J Zaleski; Nancy Savioli; Jason Lottherand; Charles Bedard; John Gill; Michael F Concino; Michael W Heartlein; Lennart Truedsson; Jan L Powell; Arthur O Tzianabos
Journal:  BMC Immunol       Date:  2010-08-20       Impact factor: 3.615

Review 8.  The alternative complement pathway revisited.

Authors:  Morten Harboe; Tom Eirik Mollnes
Journal:  J Cell Mol Med       Date:  2008-04-15       Impact factor: 5.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.